{
    "table_id": "finqa_5deea04399",
    "source": "finqa",
    "original_metadata": {
        "source_dataset": "finqa",
        "document_id": "REGN/2010/page_64.pdf-2",
        "pre_text_caption_evidence": [
            "recognition of deferred revenue related to sanofi-aventis 2019 $ 85.0 million up-front payment decreased in 2010 compared to 2009 due to the november 2009 amendments to expand and extend the companies 2019 antibody collaboration .",
            "in connection with the november 2009 amendment of the discovery agreement , sanofi-aventis is funding up to $ 30 million of agreed-upon costs incurred by us to expand our manufacturing capacity at our rensselaer , new york facilities , of which $ 23.4 million was received or receivable from sanofi-aventis as of december 31 , 2010 .",
            "revenue related to these payments for such funding from sanofi-aventis is deferred and recognized as collaboration revenue prospectively over the related performance period in conjunction with the recognition of the original $ 85.0 million up-front payment .",
            "as of december 31 , 2010 , $ 79.8 million of the sanofi-aventis payments was deferred and will be recognized as revenue in future periods .",
            "in august 2008 , we entered into a separate velocigene ae agreement with sanofi-aventis .",
            "in 2010 and 2009 , we recognized $ 1.6 million and $ 2.7 million , respectively , in revenue related to this agreement .",
            "bayer healthcare collaboration revenue the collaboration revenue we earned from bayer healthcare , as detailed below , consisted of cost sharing of regeneron vegf trap-eye development expenses , substantive performance milestone payments , and recognition of revenue related to a non-refundable $ 75.0 million up-front payment received in october 2006 and a $ 20.0 million milestone payment received in august 2007 ( which , for the purpose of revenue recognition , was not considered substantive ) .",
            "years ended bayer healthcare collaboration revenue december 31 ."
        ],
        "question": "what was the total in 2010 and 2009 for arcalyst ae net product sales?"
    },
    "dimensions": {
        "rows": 5,
        "columns": 3
    },
    "schema": {
        "columns": [
            "bayer healthcare collaboration revenue",
            "bayer healthcare collaboration revenue",
            ""
        ],
        "dtypes": {
            "bayer healthcare collaboration revenue": "object",
            "": "object"
        }
    }
}